Physician profile
Catherine E Walkington
NPI 1417480005
$1,791.20
in general payments reported to CMS, 2019-2025
15 companies · $395 in 2025
The $395 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.16 · 2022: $477 · 2023: $602 · 2024: $277 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.71 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $382.83 | 2021-2024 | |
| Hologic Sales and Service, LLC | $291.84 | 2023-2025 | Acessa Provu System, Myosure Tissue Removal Device, Aptima |
| Astellas Pharma US INC | $192.21 | 2023-2025 | Veozah |
| Abbvie INC. | $187.73 | 2021-2022 | |
| Biogen, INC. | $159.92 | 2025 | Zurzuvae |
| Amgen INC. | $114.87 | 2022-2025 | Evenity, Prolia |
| Pfizer INC. | $112.45 | 2022-2024 | |
| Millicent US INC | $64.57 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Bayer Healthcare Pharmaceuticals INC. | $60.34 | 2023-2025 | |
| Meditrina | $54.81 | 2022-2025 | |
| Organon LLC | $52.96 | 2022-2024 | |
| Evofem Biosciences, INC. | $50.97 | 2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $24.39 | 2023 | Myfembree |
| Myovant Sciences INC. | $20.79 | 2022 | |
| Sage Therapeutics, LLC | $20.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Walkington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.